RBC Capital Maintains Outperform on Sarepta Therapeutics, Raises Price Target to $182
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has maintained its 'Outperform' rating on Sarepta Therapeutics and slightly raised the price target from $181 to $182.
October 04, 2024 | 3:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reaffirmed its positive outlook on Sarepta Therapeutics by maintaining an 'Outperform' rating and slightly increasing the price target to $182.
The reaffirmation of the 'Outperform' rating and the slight increase in the price target by RBC Capital suggests continued confidence in Sarepta Therapeutics' performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100